Clinical trials using HSD17B13 RNAi have been initiated in NASH patients (https://www.clinicaltrialsarena.com/news/arrowhead-doses-first-patient-aro-hsd/). The gene discussed is HSD17B13; the disease is metabolic dysfunction-associated steatohepatitis.